You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial

Article info

Article menu

Download PDFPDF

XML
Interstitial lung disease
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial

Authors

  • Toby M Maher NIHR Respiratory Clinical Research Facility, Royal Brompton Hospital, London, UK Fibrosis Research Group, National Heart and Lung Institute, Imperial College London, London, UK PubMed articlesGoogle scholar articles
  • Tamera J Corte Department of Respiratory Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia Medical School, University of Sydney, Camperdown, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Aryeh Fischer Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA PubMed articlesGoogle scholar articles
  • Michael Kreuter Center for Interstitial and Rare Lung Diseases and Department of Pulmonology and Critical Care Medicine, Thoraxklinik, Member of the German Center for Lung Research, University of Heidelberg, Heidelberg, Germany PubMed articlesGoogle scholar articles
  • David J Lederer Divison of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Medical Center, New York City, New York, USA PubMed articlesGoogle scholar articles
  • Maria Molina-Molina Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), University Hospital of Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Madrid, Spain PubMed articlesGoogle scholar articles
  • Judit Axmann F. Hoffmann-La Roche, Ltd., Basel, Switzerland PubMed articlesGoogle scholar articles
  • Klaus-Uwe Kirchgaessler F. Hoffmann-La Roche, Ltd., Basel, Switzerland PubMed articlesGoogle scholar articles
  • Vincent Cottin National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Lyon, France Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Toby M Maher; t.maher{at}rbht.nhs.uk
View Full Text

Citation

Maher TM, Corte TJ, Fischer A, et al
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial
BMJ Open Respiratory Research 2018;5:e000289. doi: 10.1136/bmjresp-2018-000289

Publication history

  • Received May 9, 2018
  • Revised July 5, 2018
  • Accepted July 13, 2018
  • First published September 4, 2018.
Online issue publication 
June 10, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0